Mirum Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue:
Product sales, net	$90,302	$47,725	$236,979	$109,320
License and other revenue	75	—	495	7,500
Total revenue	90,377	47,725	237,474	116,820
Operating expenses:
Cost of sales	20,806	10,228	58,863	22,019
Research and development	31,710	26,117	96,604	71,674
Selling, general and administrative	50,545	36,528	145,391	99,696
Total operating expenses	103,061	72,873	300,858	193,389
Loss from operations	(12,684)	(25,148)	(63,384)	(76,569)
Other income (expense):
Interest income	3,469	4,061	10,588	9,960
Interest expense	(3,586)	(3,574)	(10,732)	(11,542)
Loss from termination of revenue interest purchase agreement	—	—	—	(49,076)
Other income (expense), net	(1,087)	1,322	982	237
Net loss before provision for income taxes	(13,888)	(23,339)	(62,546)	(126,990)
Provision for income taxes	347	249	1,606	766
Net loss	$(14,235)	$(23,588)	$(64,152)	$(127,756)
Net loss per share, basic and diluted	$(0.30)	$(0.57)	$(1.36)	$(3.28)
Weighted-average shares of common stock outstanding, basic and diluted	47,782,619	41,098,920	47,316,789	38,973,060

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.